Phase I Trial of 2-Methoxyestradiol (2ME2, Panzem(®)) NanoCrystal(®) Dispersion (NCD(®)) in Advanced Solid Malignancies

PURPOSE: 2-methoxyestradiol (2ME2, Panzem(®)) is an endogenous, estradiol-17β metabolite which at pharmacological doses exerts antimitotic and antiangiogenic activities. Studies with a 2ME2 capsule formulation showed limited oral bioavailability. We report the results of a phase I study using a Nano...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tevaarwerk, Amye J., Holen, Kyle D., Alberti, Dona B., Sidor, Carolyn, Arnott, Jamie, Quon, Check, Wilding, George, Liu, Glenn
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2009
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2892631/
https://ncbi.nlm.nih.gov/pubmed/19228747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1599
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge